One-Person trial aims to tackle rare genetic brain disease

NCT ID NCT07222371

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a custom-made drug called an antisense oligonucleotide in a single person with TUBB4A-related leukodystrophy, a rare genetic disorder that affects the brain's white matter. The drug is designed to target the specific genetic mutation causing the disease. Researchers will measure changes in movement, dystonia (involuntary muscle contractions), and daily functioning over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

personalized antisense oligonucleotide (nL-TUBB4-001)

What this could lead to

If it works, this could point toward a treatment for TUBB4A-related leukodystrophy, a rare genetic brain disorder.

What could go wrong

This is a very early, single-participant study, so results may not apply to others. The treatment is experimental and risks are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENETIC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary disease TUBB4A-related neurologic disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rady Children's Hospital San Diego

    San Diego, California, 92123, United States